Semaglutide vs. Ozempic: Are They Actually the Same Thing?

Semaglutide is the active molecule; Ozempic is one branded product that contains it. The two terms are not interchangeable — and that distinction has real consequences for dosing, insurance coverage, and whether the vial you're buying is FDA-regulated.

What Semaglutide Actually Is

Semaglutide is a GLP-1 receptor agonist — a modified analog of the gut hormone GLP-1, engineered with a fatty acid side chain that extends its half-life to roughly one week. Novo Nordisk packages the same peptide under three distinct brand names: Ozempic (weekly injection, approved for type 2 diabetes and cardiovascular risk), Wegovy (weekly injection at higher doses, approved for obesity), and Rybelsus (daily oral tablet for diabetes). The STEP-1 trial, published in the New England Journal of Medicine, used the Wegovy formulation at 2.4 mg weekly and produced a mean 14.9% body weight loss — a result that would not have been replicated with Ozempic's maximum 2 mg diabetic dose.

Brand name, dose, and indication are three separate variables. Prescribing Ozempic for weight loss is technically off-label; Wegovy is the on-label obesity product. Insurers treat them differently, which is why the brand distinction matters beyond semantics. For a deeper look at how these drugs compare head-to-head, see our Mounjaro vs. Ozempic breakdown for men with diabetes and obesity.

The "Generic Semaglutide" Problem

There is no FDA-approved generic semaglutide as of July 2026. What the market calls "generic semaglutide" is almost entirely compounded product — manufactured by 503A or 503B pharmacies using semaglutide salts (typically semaglutide sodium or acetate) that are not the same molecular form used in Ozempic or Wegovy. The FDA has explicitly flagged these salt-form differences as a safety and equivalency concern.

The SELECT trial (NEJM, 2023) established Ozempic-grade semaglutide's cardiovascular benefit in a non-diabetic obese population — a 20% reduction in MACE over roughly 34 months. That data was generated with pharmaceutical-grade semaglutide base, not a compounded acetate salt. Whether compounded versions replicate that pharmacokinetic profile is unproven. Clinicians sourcing GLP-1 therapy through a structured program — such as those listed at Marek Health via our peptide therapy directory — typically use licensed pharmacy channels with documented assay verification.

If you're weighing the thyroid risk language on semaglutide's label, the FDA's REMS requirement and c-cell tumor flagging apply to branded GLP-1 products; compounded versions carry no equivalent regulatory warning infrastructure. Our full review of what the tumor data actually shows covers this in detail.

Frequently asked questions

Is semaglutide the same drug as Ozempic?

Semaglutide is the active ingredient in Ozempic, but the two terms are not identical. Ozempic is one specific branded formulation — a weekly injectable approved for type 2 diabetes and cardiovascular risk reduction — while semaglutide also appears in Wegovy (obesity, higher dose) and Rybelsus (oral, diabetes). The peptide molecule is the same; the indications, doses, and regulatory approvals differ by brand.

Can I substitute compounded semaglutide for Ozempic?

No direct substitution is validated. Compounded semaglutide typically uses salt forms not present in FDA-approved products, and no bioequivalence data confirms these formulations match Ozempic's pharmacokinetics. The SURMOUNT-1 and STEP clinical trial datasets — both published in NEJM — were built on pharmaceutical-grade semaglutide base. Patients considering compounded versions should do so through a licensed prescriber who can monitor dosing and adverse effects, and should understand they are using an unapproved formulation. See our advanced therapies treatment hub for vetted provider options.

What is the cheapest legitimate way to access semaglutide in 2026?

For commercially insured patients, Novo Nordisk's savings cards reduce Ozempic copays to as low as $25/month for eligible adults. Self-pay patients using the Wegovy oral pill (approved late 2025, broadly available in 2026) can access starting doses for approximately $149/month through manufacturer programs or GoodRx pricing. Compounded versions via telehealth platforms run lower still, but carry the regulatory and potency caveats described above. Saxenda (liraglutide) remains an older, often cheaper GLP-1 alternative, though its weight-loss efficacy is substantially lower than semaglutide at any dose.